Navigation Links
Researchers get $7.5M grant to combat nerve agents
Date:11/14/2011

op the deadly chemicals before they can attach in the first place. They have engineered souped-up versions of naturally occurring human enzymes that will scavenge nerve agents from the bloodstream. No tests involving actual nerve agents will take place at Ohio State.

"Nerve agents like sarin, and even related pesticides, are a significant threat in the hands of terrorists, and we're really lacking in ways to treat mass casualties," said Magliery, co-leader of the new Ohio State center. "Fortunately, there are enzymes already in human blood that can deactivate these agents. We just have to engineer them to be more efficient, and we have to be able to produce and formulate them as drugs."

Hadad leads an effort to model the chemical structure of candidate enzymes on the powerful parallel supercomputer systems at OSC, while Magliery is producing synthetic versions of the new enzymes for further testing and preclinical evaluation by the Army.

"The preliminary results from the first round of this grant showed that these enzymes can be engineered to have enough activity to use as therapeutic agents," said Magliery. "But there are still challenges ahead. There are a lot of related agents, and there are few enzymes used as drugs today."

Hadad outlined one of the main challenges. "In nature, each enzyme generally has only one function one thing that it does very well," he said. "But we need an enzyme that will deactivate many different nerve agents.

"We need one molecule that can do it all."

Magliery added that the ideal enzyme would remain active for days or weeks at a time, pulling toxic agents from the body over and over again. It could be administered as an antidote immediately after an attack, or as an inoculation against future attacks.

Soldiers and first responders are among the likely recipients of such a preventive dose, but so are people whose jobs regularly expose them to nerve agents, eve
'/>"/>

Contact: Mr. Jamie Abel
jabel@osc.edu
614-292-6495
Ohio Supercomputer Center
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Researchers uncover why the body cant defend against tuberculosis
2. Results triple researchers projections with use of adult stem cells for heart failure
3. Researchers develop more effective way to discover and test potential cancer drugs
4. Researchers closer to the super bug puzzle
5. Einstein researchers discover key to cell specialization
6. 200 thousand dollars awarded to genomics researchers to spark new research technology development
7. Becoming part of global, shoestring team requires researchers only to play fair, share
8. Pitt researchers develop eButton, an easier way to monitor food intake, exercise, and lifestyle
9. Berkeley Lab researchers create first of its kind gene map of sulfate-reducing bacterium
10. Do plants perform best with family or strangers? Researchers consider social interactions
11. University of Saskatchewan, Royal Ontario Museum researchers track half-billion year old predator
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers get $7.5M grant to combat nerve agents
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... of the "Global Wearable Technologies Market and ... Overview, Trends and Forecast 2014-2020" report to ... are smart devices that can be worn on ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ) ... Global Watermarking and Fingerprinting Markets" report to ... This insight provides an overview ... markets. Watermarking aims to control and monitor piracy ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2
... Crop Science Society of America (CSSA) announces the following 2012 ... Oct. 21-24, 2012 in Cincinnati, OH. Members of the Society ... service. Only 0.3 percent of the Society,s active and emeritus ... Fellows are: Marc C. Albertsen, Dupont Pioneer - ...
... must account for the complexity of the human impact ... and temporal scales. "Scale-sensitive research" emerges as a new, ... analyses, and tools to the scale in which these ... that the decisions they take resolve ecological problems at ...
... - When Washington State University and U.S. Department of Agriculture ... a rare but deadly infection was discovered among a group ... adrenaline. Not only were the horses infected with a parasitic ... the outbreak was at no ordinary ranch. It ...
Cached Biology News:Crop Science Society of America presents 2012 class of fellows 2Crop Science Society of America presents 2012 class of fellows 3Scientists call policy-makers to be scale-aware 2Scientists call policy-makers to be scale-aware 3WSU/USDA scientist creates test, treatment for malaria-like sickness in horses 2WSU/USDA scientist creates test, treatment for malaria-like sickness in horses 3WSU/USDA scientist creates test, treatment for malaria-like sickness in horses 4
(Date:1/22/2015)... 22, 2015 Eckert & Ziegler Vitalea ... (AMS) services to the pharmaceutical and biotech industry, has ... company in the position of Director of Science & ... and valuable experience in drug metabolism and bioanalysis to ...
(Date:1/22/2015)... RBJ today announces the firm brokered a long-term lease totaling ... biopharmaceutical company, at Two Ledgemont Center in Lexington, ... president, and Brian Cohen , senior vice president, represented ... 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... 2015 Crystal Diagnostics (CDx) Xpress System, a ... received AOAC-PTM Certifications for the six non-O157 Shiga toxin-producing E. ... referred to as STEC or the “Big-6”) as well as ... (cfu) per 325 g of raw ground beef and raw ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project ... the legal requirements around using controlled substances in pharmaceutical ... As their international operations expand and become increasingly complex, ... as a result of the first phase of the ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Global Compliance Service for Controlled Substances to Expand to China 2
... at the Diabetes... -- JERUSALEM, November 15, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
... Kienberger received the 2010 ICO Prize for pioneering contributions ... this new scientific discipline is to capture snapshots of ... to yield important insights into the actual course of ... and the interactions between light and matter. "An ...
... CAMBRIDGE, Massachusetts, November 12, 2010 ... ... lpUnit=,PRN,; --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
Cached Biology Technology:Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD 2Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD 3Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD 4Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD 5Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD 6Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD 7Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD 8Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD 92010 ICO Prize is awarded to TUM physicist Reinhard Kienberger 2Cell Press Delivers the News 2Cell Press Delivers the News 3Cell Press Delivers the News 4Cell Press Delivers the News 5Cell Press Delivers the News 6Cell Press Delivers the News 7
... low background ,This solution greatly enhances antigen-antibody ... than obtained with conventional methods. ,Two kinds ... secondary antibodies, which can suppress the background ... Wide versatility ,It is applicable to various ...
Mouse Anti-Human Killer Cell Immunoglobulin-like Receptor, Two Domains, Long Cytoplasmic Tail, 2 (KIR2DL2 (KIR2DL3 Monoclonal Antibody Family: Immunoglobulin Sub-Family: not assigned-Immunogl...
pH-dependent fluorescence; Maximum intensity observed in basic solutions....
Mouse anti human pro-Relaxin-2...
Biology Products: